ClinicalTrials.gg
CompletedNCT04805398Updated Jun 29, 2022

Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1)

A Phase 2 interventional study of CM310 and Placebo in Chronic Rhinosinusitis (Diagnosis) and Nasal Polyps, sponsored by Keymed Biosciences Co.Ltd. Completed at 19 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-29.

Primary conditionNasal PolypsRegistry: DiseaseReclassifiedWhy we changed it
Registry
Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Nasal Polyps
Why
  1. Disease describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Nasal Polyps.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.

Enrollment
33rd of 43
56 · median 90
Started
2021
with 3 others
Phase 2
13 of 46
4 open now
Registered
11th of 46
by date
Lead sponsor
4 of 46
Keymed Biosciences Co.Ltd

Among the 46 studies in Nasal Polyps with a site in China, this one is the 33rd largest by enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2021, is one of 13 in phase 2, and was the 11th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Nasal Polyps with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of CM310 in comparison to placebo in addition to a background treatment of mometasone furcate nasal spray (MFNS) in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).

Read the detailed description

The study consists of a Screening/run-in Period (up to 4 weeks), a Randomized, Double Blind Treatment Period (16 weeks, till End-of-Treatment Visit) and a Safety Follow-up Period (8 weeks, till End-of-Study Visit).

56 patients who meet eligibility criteria will be randomized 1:1 to receive either CM310 300mg or matched placebo subcutaneously every two weeks (Q2W) for a total of 8 times. All patients will receive MFNS on a daily basis as a background treatment throughout the study. MFNS is required to use no less than 14 days during Screening/run-in Period.

Central reading will be implemented to nasal endoscopic nasal polyp score (NPS) , CT scans to Lund-Mackay score and volume of the involved area of nasosinusitis on 3D-construction images, and nasal polyp biopsy tissue analysis to eosinophil counts \& percentage.

03

Conditions studied

  • Chronic Rhinosinusitis (Diagnosis)
  • Nasal Polyps

Browse trials for

Keywords

  • Chronic Rhinosinusitis with Nasal Polyps
04

In context

Nasal Polyps Reclassified

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

This study's enrollment of 56 is close to the median of 60 across 181 interventional studies indexed under Nasal Polyps.

Browse Nasal Polyps studies →

Lead sponsor

Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.

Compared within Nasal Polyps, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bilateral CRSwNP.
  • Prior treatment with systemic (SCS), and/or contraindicate to or intolerance to SCS, and/or with prior surgery to nasal polyps.
  • Stable dose of intranasal corticosteroids for at least 4 weeks before screening.
  • Ongoing symptoms for at least 4 weeks before screening:1)Nasal congestion/obstruction; 2)Othe symptom, e.g., loss of smell or rhinorrhea.
  • Bilateral NPS of ≥5 with a minimum score of 2 in each nasal cavity at screening and at baseline.
  • NCS score of 2 or 3 at screening and at baseline.
  • Eosinophilic level meets the one of the following criteria: 1) serum eosinophil count ≥6.9% (without concomitant asthma) or ≥3.7% (with concomitant asthma) at screening; 2) absolute count of ≥55 per high power field or percentage of ≥27% in eosinophil level from nasal polyps biospy tissue.
  • .

Exclusion criteria

Exclusion Criteria:

  • Not enough washingout period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for IL-4Rα antagonists, less than 8 weeks or 5 half-lives for biologic therapy/systemic , less than 6 months for sinus surgery (including polypectomy).
  • concurrent disease, e.g., ongoing rhinitis medicamentosa, acute sinusitis, nasal infection or upper respiratory infection, allergic fungal rhinosinusitis, , uncontrolled chronic disease such as cardivascular diseases, tuberculosis, diabetes etc.
  • Allergic or intolerant to mometasone furoate spray or CM310/placebo.
  • Significant liver or renal dysfunction.
  • Other.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    CM310

    CM310 300mg is given subcutaneously (SC) every two weeks for 16-week treatment

    Biological: CM310

  • Placebo comparator
    Placebo

    Placebo is given subcutaneously (SC) every two weeks for 16-week treatment.

    Biological: Placebo

Interventions

  • BiologicalCM310

    300 mg every two weeks

  • BiologicalPlacebo

    300 mg every two weeks

07

What researchers measure

Primary outcomes

  1. Bilateral endoscopic Nasal Polyps Score (NPS)

    Change from baseline in the bilateral endoscopic NPS.NPS score ranges from 0-8. (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

    Time frame: at Week 16

  2. Nasal Congestion/Obstruction SymptomSeverity (NCS) Score

    Change from baseline in the NCS score. NCS score (0-3), higher score means worse nasal symptom.

    Time frame: at Week 16

Secondary outcomes

  1. Time to the first response of NPS

    Time to the first response of NPS (defined as bilateral endoscopic NPS improved ≥1).

    Time frame: Baseline up to Week 24

  2. Lund-Mackay score

    Change from baseline in the Lund-Mackay score on CT scan. The range of LM score is 0-24. Higher score means worse nasosinusitis.

    Time frame: at Week 16

  3. Volume of the involved area of nasosinusitis on 3D-construction CT scan

    Change from baseline in the volume of the involved area of nasosinusitis on 3D-construction CT scan.

    Time frame: at Week 16

  4. Bilateral endoscopic NPS

    Change from baseline in the bilateral endoscopic NPS.

    Time frame: at Week 8

  5. Proportion of subjects receiving rescue therapy for nasal polyps

    Proportion of subjects receiving rescue therapy for nasal polyps.

    Time frame: Baseline up to Week 24

  6. University of Pennsylvania Smell Identification Test (UPSIT)

    Change from baseline in UPSIT. UPSIT score (0-40). Higher score means better sense of smell.

    Time frame: at Week 16

  7. 22-item Sino-nasal Outcome Test Scores(SNOT-22) score

    Change from baseline in SNOT-22 score. SNOT-22 score (0-110). Higher score means a worse outcome.

    Time frame: at Week 16

  8. Total Symptom Score(TSS) score

    Change from baseline in TSS score. TSS score (0-9). Higher score means worse nasal symptom.

    Time frame: at Week 16

  9. Bilateral endoscopic NPS

    Change from baseline in the bilateral endoscopic NPS in subjects with concurrent asthma.

    Time frame: at Week 16

  10. Bilateral endoscopic NCS

    Change from baseline in the NCS in subjects with concurrent asthma.

    Time frame: at Week 16

  11. Safety parameters

    Incidence of treatment-emergent adverse events (TEAEs), of treatment-emergent serious AEs (TESAEs), etc.

    Time frame: Baseline up to Week 24

  12. Pharmacokinetics(PK)

    Trough concentration and exposure.

    Time frame: Baseline up to Week 24

  13. Pharmacodynamics(PD)

    Change from baseline in serum biomarker level (TARC, total IgE and eosinophil level).

    Time frame: Baseline up to Week 24

  14. PD(eosinophil level in nasal polyps biospy tissue)

    Change from baseline of eosinophil level in nasal polyps biospy tissue.

    Time frame: at Week 16

  15. Anti-drug antibodies(ADA)

    Incidence of ADA.

    Time frame: Baseline up to Week 24

  16. Neutralizing antibody (Nab)

    Incidence of Nab.

    Time frame: Baseline up to Week 24

08

Study locations

19 sites
  • Beijing Chaoyang Hospital, CMU
    Beijing, Beijing, China
  • Beijing Hospital
    Beijing, Beijing, China
  • Beijing Renmin Hospital
    Beijing, Beijing, China
  • Beijing Tongren Hospital, CMU
    Beijing, Beijing, China
  • First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • Jingzhou Central Hospital
    Jingzhou, Hubei, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei, China
  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong, China
  • Shandong Second Provincial General Hospital (Shandong ENT hospital)
    Jinan, Shangdong, China
  • Renji Hospital of Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
  • Tongji Hospital of Tongji University
    Shanghai, Shanghai, China
  • Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • Hospital of Chengdu University of Traditional Chinese Medicine
    Chengdu, Sichuan, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Mar 2022, 11 months.

Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2021
First posted
Mar 18, 2021
StartActual
Apr 6, 2021
Primary completionActual
Mar 18, 2022
CompletionActual
Mar 18, 2022
Last update
Jun 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04805398
Responsible party
Sponsor
First posted
Mar 18, 2021
Start date
Apr 6, 2021
Primary completion
Mar 18, 2022
Completion
Mar 18, 2022
Last update
Jun 29, 2022

Study contacts

Luo Zhang
principal investigator · Beijing Tongren Hospital, CMU

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion